冠脉内联合注射罂粟碱和替罗非班对PCI术中无复流的疗效观察
发布时间：2019-01-30 14:53
【摘要】：为了评价PCI中冠状动脉内联合应用罂粟碱及替罗非班与维拉帕米及替罗非班对急性心肌梗死无复流的疗效及安全性。选择2014年1月~2016年7月笔者所在科室收治的急性ST段抬高心肌梗死行急诊PCI,梗死相关动脉开通后无复流患者108例,随机分为观察组和对照组各54例。两组患者手术方法相同,出现无复流现象后给予替罗非班,观察组给予罂粟碱,对照组给予维拉帕米。观察两组注射药物后无复流恢复时间、TMPG分级、术后1小时心电图ST段回落、左心功能及住院期间的主要心血管事件。观察组无复流恢复时间、TIMI血流分级、TMPG分级、心电图ST段回落、左室射血分数均优于对照组(P0.05),观察组住院期间的MACE发生率低于对照组(P0.05)。研究表明AMI行急诊PCI出现无复流给予罂粟碱和替罗非班,可以增加STEMI患者PCI术中发生无复流现象后冠状动脉血流和心肌组织灌注,减少术后心绞痛及MACE的发生率,且未增加围手术期不良事件的发生。
[Abstract]:To evaluate the efficacy and safety of combined intracoronary administration of papaverine, tirofiban, verapamil and tirofiban in the treatment of acute myocardial infarction without reflow in PCI. From January 2014 to July 2016, 108 patients with acute ST segment elevation myocardial infarction were randomly divided into two groups: observation group (n = 54) and control group (n = 54). The two groups were treated with tirofiban after no reflow, the observation group with papaverine and the control group with verapamil. No reflow recovery time, TMPG grade, ST segment fall 1 hour after injection, left ventricular function and main cardiovascular events during hospitalization were observed in the two groups. No reflow recovery time, TIMI blood flow grading, TMPG grading, ECG ST segment drop, left ventricular ejection fraction were better than the control group (P0.05), the incidence of MACE during hospitalization in the observation group was lower than that in the control group (P0.05). The results showed that the occurrence of no reflow of papaverine and tirofiban in emergency PCI with AMI could increase coronary blood flow and myocardial perfusion after PCI in STEMI patients, and reduce the incidence of angina pectoris and MACE. The incidence of adverse events in perioperative period was not increased.
【作者单位】： 大连市友谊医院心内科;
【基金】：2016年北京力生心血管健康基金会领航基金项目(LHJJ201611007)
【分类号】：R542.22
，
本文编号：2418245
[Abstract]:To evaluate the efficacy and safety of combined intracoronary administration of papaverine, tirofiban, verapamil and tirofiban in the treatment of acute myocardial infarction without reflow in PCI. From January 2014 to July 2016, 108 patients with acute ST segment elevation myocardial infarction were randomly divided into two groups: observation group (n = 54) and control group (n = 54). The two groups were treated with tirofiban after no reflow, the observation group with papaverine and the control group with verapamil. No reflow recovery time, TMPG grade, ST segment fall 1 hour after injection, left ventricular function and main cardiovascular events during hospitalization were observed in the two groups. No reflow recovery time, TIMI blood flow grading, TMPG grading, ECG ST segment drop, left ventricular ejection fraction were better than the control group (P0.05), the incidence of MACE during hospitalization in the observation group was lower than that in the control group (P0.05). The results showed that the occurrence of no reflow of papaverine and tirofiban in emergency PCI with AMI could increase coronary blood flow and myocardial perfusion after PCI in STEMI patients, and reduce the incidence of angina pectoris and MACE. The incidence of adverse events in perioperative period was not increased.
【作者单位】： 大连市友谊医院心内科;
【基金】：2016年北京力生心血管健康基金会领航基金项目(LHJJ201611007)
【分类号】：R542.22
，
本文编号：2418245
本文链接：https://www.wllwen.com/yixuelunwen/xxg/2418245.html
最近更新
教材专著
